Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT01281150 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm
Estrogen Receptor Negative
Estrogen Receptor Positive
HER2/Neu Negative
Male Breast Carcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Triple-Negative Breast Carcinoma

Interventions

DRUG: Carboplatin
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel
OTHER: Pharmacological Study
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)